Next Article in Journal
Effect of 6-Shogaol on the Glucose Uptake and Survival of HT1080 Fibrosarcoma Cells
Previous Article in Journal
The Antitumor Didox Acts as an Iron Chelator in Hepatocellular Carcinoma Cells
Previous Article in Special Issue
Proximal Pathway Enrichment Analysis for Targeting Comorbid Diseases via Network Endopharmacology
Open AccessConcept Paper

Methylxanthines: Potential Therapeutic Agents for Glioblastoma

1
PECEM, Faculty of Medicine, National Autonomous University of México, México City 04510, Mexico
2
Neuroimmunology and Neuro-oncology Unit, National Institute of Neurology and Neurosurgery, México City 14269, Mexico
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2019, 12(3), 130; https://doi.org/10.3390/ph12030130
Received: 5 July 2019 / Revised: 24 August 2019 / Accepted: 1 September 2019 / Published: 7 September 2019
(This article belongs to the Special Issue Old Pharmaceuticals with New Applications)
Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Currently, treatment is ineffective and the median overall survival is 20.9 months. The poor prognosis of GBM is a consequence of several altered signaling pathways that favor the proliferation and survival of neoplastic cells. One of these pathways is the deregulation of phosphodiesterases (PDEs). These enzymes participate in the development of GBM and may have value as therapeutic targets to treat GBM. Methylxanthines (MXTs) such as caffeine, theophylline, and theobromine are PDE inhibitors and constitute a promising therapeutic anti-cancer agent against GBM. MTXs also regulate various cell processes such as proliferation, migration, cell death, and differentiation; these processes are related to cancer progression, making MXTs potential therapeutic agents in GBM. View Full-Text
Keywords: brain tumors; natural alkaloids; drug repositioning brain tumors; natural alkaloids; drug repositioning
Show Figures

Figure 1

MDPI and ACS Style

Pérez-Pérez, D.; Reyes-Vidal, I.; Chávez-Cortez, E.G.; Sotelo, J.; Magaña-Maldonado, R. Methylxanthines: Potential Therapeutic Agents for Glioblastoma. Pharmaceuticals 2019, 12, 130.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop